Story

Oncology Drug Developer Genhouse Bio Refiles for Hong Kong IPO

ENTHMSVIIDZHZH-TWJAKOHI
Aug 9, 20261 min read
Oncology Drug Developer Genhouse Bio Refiles for Hong Kong IPO
Text size
Background

Chinese biopharmaceutical company Genhouse Bio has officially refiled for an initial public offering on the main board of the Hong Kong Stock Exchange (HKEX), marking its second attempt to go public this year. According to an exchange disclosure on August 7, Huatai International is acting as the sole sponsor for the proposed listing.

Second Listing Attempt

This latest application follows the lapse of Genhouse Bio's previous submission. The company first filed for a Hong Kong IPO in January, but that application expired in July after the standard six-month review period without a hearing.

The renewed filing restarts the listing process, signaling the company's continued commitment to accessing public capital markets to fund its research and development activities.

Oncology-Focused Pipeline

Sample IUX Markets – In-articleAd

Founded in 2014, Genhouse Bio focuses on developing innovative targeted therapies for cancer. The company's pipeline is centered around the RAS signaling pathway and synthetic lethality mechanisms, two key areas in modern oncology research.

According to its prospectus, the company has eight drug candidates in development. Key details include:

  • Core Product: The lead asset is GH21, an allosteric SHP2 inhibitor.
  • Clinical Stage: GH21 is currently in Phase 2 clinical trials.
  • Positioning: The company describes GH21 as a potential best-in-class therapy in its category.

A successful IPO would provide significant capital for Genhouse Bio to advance GH21 through later-stage clinical trials and further develop its broader pipeline of cancer treatments.

Read next

More on Stocks
Back to latest news

LATEST